📋 Clinical Overview

A synergistic, long-acting, fixed-dose combination antibacterial agent belonging to the sulfonamide and diaminopyrimidine classes. It provides sequential dual blockade of the bacterial folate synthesis pathway, leading to bactericidal activity against a wide range of susceptible organisms. Its long half-life allows for less frequent dosing, improving patient compliance.

💊 Dosage & Administration

Adult: One tablet (Sulfamethopyrazine 400mg + Trimethoprim 80mg) once daily. For severe infections, initial dose may be two tablets on the first day, followed by one tablet daily.
Pediatric: For children >2 months: Dose based on Trimethoprim component (6-12 mg/kg/day) and Sulfamethopyrazine. A common regimen is 1/2 to 1 tablet once daily, depending on weight and age. Not recommended for infants <2 months.
Renal Adjusment: Creatinine Clearance (CrCl) 15-30 mL/min: Administer standard dose every 24-48 hours. CrCl <15 mL/min: Contraindicated. Monitor serum levels if possible.
Hepatic Adjusment: Use with caution in impairment. No specific quantitative guidelines; monitor for signs of toxicity.
Instruction: Administer orally with a full glass of water. Can be taken with or without food, but taking with food may reduce GI upset. Maintain adequate fluid intake (at least 2-3 liters daily) to prevent crystalluria. Complete the full prescribed course.

⚠️ Contraindications

History of hypersensitivity to sulfonamides, trimethoprim, or any component
Documented megaloblastic anemia due to folate deficiency
Marked hepatic damage
Severe renal impairment (CrCl <15 mL/min)
Porphyria
Infants less than 2 months of age (risk of kernicterus)

🔬 Mechanism of Action

The combination acts synergistically via sequential inhibition of two consecutive enzymes in the bacterial folate biosynthesis pathway. Sulfamethopyrazine, a sulfonamide, is a structural analog of para-aminobenzoic acid (PABA). It competitively inhibits dihydropteroate synthase, preventing the incorporation of PABA into dihydrofolic acid. Trimethoprim inhibits dihydrofolate reductase, the next enzyme in the pathway, preventing the conversion of dihydrofolic acid to tetrahydrofolic acid. This dual blockade depletes tetrahydrofolate, a crucial cofactor for bacterial DNA, RNA, and protein synthesis, leading to bactericidal effects.

🤕 Side Effects

Nausea, vomiting
Anorexia, loss of appetite
Mild skin rash or pruritus
Headache

🤰 Special Populations

Pregnancy: Category D (Indian/old FDA). Trimethoprim is a folate antagonist. Avoid in first trimester (teratogenic risk) and near term (risk of kernicterus). Use only if potential benefit justifies the potential fetal risk.

Lactation: Both drugs are excreted in breast milk. Sulfonamides may cause kernicterus in jaundiced, G6PD-deficient, or ill infants. Use with caution; consider alternative or discontinue nursing.

Alcohol: Avoid. May potentiate CNS effects (dizziness) and increase risk of GI upset. Rare risk of disulfiram-like reaction.

Driving: May cause dizziness or headache. Patients should not drive or operate machinery until they know how the medicine affects them.

🔄 Drug Interactions

Warfarin: Increased anticoagulant effect, risk of bleeding Major
Methotrexate: Increased methotrexate toxicity (bone marrow suppression, hepatotoxicity) Major
Phenytoin: Increased phenytoin levels, risk of toxicity Major
Sulfonylureas (e.g., Glipizide): Enhanced hypoglycemic effect Moderate
Cyclosporine: Increased risk of nephrotoxicity and reduced cyclosporine efficacy Moderate
ACE Inhibitors (e.g., Ramipril): Increased risk of hyperkalemia Moderate
Thiazide Diuretics: Increased risk of thrombocytopenia Moderate
Rifampicin: Increased metabolism of trimethoprim, reducing efficacy Moderate

🔁 Alternatives to Bactrim-DS (Note: Original Bactrim is Sulfamethoxazole+Trimethoprim)

Same composition (Sulfamethopyrazine (400mg) + Trimethoprim (80mg)), different brands:

Ciplen-DS Sulprim-DS Sulfatrim-DS Eltri DS